Addex Therapeutics Ltd. (ADXN) - Price to Earnings Multiple
Addex Therapeutics (ADXN) developments are stalling due to reagent shortages and disruptions at European centers, although drug synthesis in laboratories remains on schedule following equipment upgrades. Risks are further amplified by Asian import difficulties and patent disputes. The current metric stands at -0.30, which is clearly demonstrated by the price action shown below for this neuro-drug manufacturer.
Analytical breakdowns for Addex Therapeutics, Ltd. (ADXN)
- price and consensus price forecast:
- market capitalization indicators:
- issuer book value statistics:
- debt and solvency information:
Debt to Equity Ratio Addex Therapeutics|ADXN - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Addex|ADXN - Company Total Debt|Debt to Book Capital Addex Therapeutics Ltd|ADXN - Company Long-Term Debts|Company Short-Term Loans and Borrowings Addex Therapeutics|Immediate Liquidity addextherapeutics.com
- financial results and valuation multiples details:
ADXN - Company Net Income|Expected Net Income Addex Therapeutics|ADXN - P/E Multiple|Forward P/E Multiple Addex Therapeutics Ltd.|ADXN - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Addex Therapeutics Ltd|ADXN - Operating profit EBITDA|Net earnings per one share for the last twelve months Addex Therapeutics|ADXN - Net earnings per share for the last 12 months|Quarterly EPS earnings growth addextherapeutics.com|ADXN - Net earnings per share growth this year|Projected earnings per share increase next year Addex Therapeutics
General company analysis:addextherapeutics.com, ADXN
The P/E ratio determines the market value of a single unit of profit, reflecting investor expectations regarding future cash flows. By analyzing the P/E valuation profile of a company, one can identify whether an asset is overbought or possesses growth potential. The metric is calculated as the ratio of the current share price to earnings per share. For Addex Therapeutics (ADXN), this indicator is sensitive to Phase 2 clinical trial successes and patent payments. The trend of this metric confirms investment attractiveness as progress is made in the treatment of Parkinson's disease.
Key competitors
P/E Multiple biogen.com|P/E Multiple NBIX|Regencell Bioscience Ltd - Price to Earnings Multiple|P/E Multiple AXSM (Axsome Therapeutics Inc)|ACAD: Price to Earnings Multiple|Xenon Pharmaceuticals - P/E Multiple|Market Cap to Earnings vikingtherapeutics.com|SUPN (Supernus) - Price to Earnings Ratio|Price to Earnings Multiple CPRX|Price to Earnings Ratio DNLI|HRMY: Company Value to Net Income|Price to Earnings Ratio BHVN (Biohaven Ltd.)|Market Price to Net Income Ratio AMLX|P/E Multiple TRVI (Trevi Therapeutics, Inc.)|Company Value to Net Income PRAX|Anavex Corp - P/E Multiple|Market Cap to Earnings CeriBell EEG|prothena.com (PRTA) - Price to Earnings Ratio|Alector - Company Value to Net Income|ANNX (Annexon) - P/E Multiple|P/E Multiple Omeros Corp.|Price to Earnings Ratio Neurogene Corp (NGNE)|ACIU: Market Cap to Net Income|P/E Multiple VYGR (Voyager Therapeutics)|neumoratx.com (NMRA) - Market Cap to Earnings|SCLX: Price to Earnings Ratio|TVGN - P/E Multiple|ACOG (alphacognition.com) - Price to Earnings Ratio|CGTX: Market Price to Net Income Ratio|IKT (Inhibikase Therapeutics) - P/E Multiple|cassavasciences.com (SAVA) - Business Payback Period|P/E Multiple ASRT|Price to Earnings Ratio coyatherapeutics.com COYA|Price to Earnings Ratio Vistagen VTGN|Business Payback Period Ovid Therapeutics Inc (OVID)|Acumen Pharmaceuticals - P/E Multiple|CRVO - P/E Multiple|ATHE: P/E Multiple|Price to Earnings Multiple CLNN|Price to Earnings Ratio PEPG|Price to Earnings Multiple JUNS (Jupiter Neurosciences, Inc.)|Price to Earnings Ratio Relmada Therapeutics (RLMD)|annovisbio.com - Price to Earnings Multiple|Price to Earnings Ratio Grace Therapeutics GRCE|AIFF: Price to Earnings Multiple|ANEW Medical, Inc. - P/E Multiple|Market Cap to Earnings NeuroSense Therapeutics|RVPH (Reviva Pharmaceuticals) - Price to Earnings Ratio|MetaVia (MTVA) - P/E Multiple|Price to Earnings Ratio NeurAxis|HSDT: Company Value to Net Income|Price to Earnings Ratio Passage Bio, Inc. (PASG)|NEUP - Market Cap to Earnings|P/E Multiple NERV (Minerva Neurosciences)|P/E Multiple athira.com ATHA|Alzamend - P/E Multiple|CYCN (Cyclerion Therapeutics) - Price to Earnings Multiple|PTIX: P/E Multiple|Price to Earnings Multiple KTTA|CRGT (Cortigent Inc) - P/E Multiple|Market Cap to Earnings avenuetx.com ATXI|Price to Earnings Ratio BCLI (BrainStorm Cell Therapeutics)|Cara Therapeutics Inc. - Price to Earnings Multiple|Chromocell Therapeutics Corporation - Price to Earnings Ratio|Company Value to Net Income ELYM|ITCI: Price to Earnings Ratio|longboardpharma.com - Market Price to Net Income Ratio|MRNS: P/E Multiple|NKGen Biotech Inc - Company Value to Net Income|NRBO (NeuroBo) - P/E Multiple|Market Cap to Earnings Sage Therapeutics Inc SAGE|Price to Earnings Ratio Synaptogenix, Inc. (SNPX)|TRVN (trevena.com) - Company Value to Net Income|P/E Multiple VIGL (Vigil Neuroscience, Inc.)|P/E Multiple anewmeds.com WENA|CERE - Price to Earnings Ratio
